IQV IQVIA HoldingsWatchlist
About IQVIA Holdings Company
IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission critical information, technology solutions, and real-world solutions and services to the firm's life science clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial related services. The Contract Sales and Medical Solutions segment offers health care provider and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1982 and is headquartered in Durham, NC.
Price Over Earnings Overview: IQVIA Hldgs
Looking into the current session, IQVIA Hldgs Inc. (NYSE:IQV) shares are trading at $212.73, after a 0.95% spike. Moreover, over the past month, the stock went up by 17.57%, but in the past year, fell
What Does IQVIA Holdings Inc.'s (NYSE:IQV) Share Price Indicate?
Analysts Are Bullish on These Healthcare Stocks: IQVIA Holdings (IQV), Biogen (BIIB)
$Simon Property(SPG.US)$, $Take-Two Interactive Software(TTWO.US)$, and $Tyson Foods(TSN.US)$ report on Monday, followed by $BP PLC(BP.US)$, $DuPont(DD.US)$, and $Royal Caribbean(RCL.US)$.
$Disney(DIS.US)$, $CVS Health(CVS.US)$, and ...
Piper Sandler analyst Edward Yruma upgraded $Target(TGT.US)$ to Overweight from Neutral with a price target of $200, up from $190. The company has had a difficult 2022, but we are approaching "trough" EBIT margins and the stock's valuation now "looks compelling," Yruma tells investors in a research note.
Canaccord Starts Estee Lauder With Hold, Sees Estimate Risk